ECALTACopy

• DRUGBANK - Anidulafungin
• indication:

  For use in the treatment of the following fungal infections: Candidemia and other forms of <i>Candida</i> infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.

• pharmacology:

• mechanism:

  Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.

• toxicity:

  During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).

• absorprion:

• halflife:

  40-50 hours

• roouteelimination:

  Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.

• volumedistribution:

  * 30 to 50 L

• clearance:

  * 1 L/h